Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...
Almost no other industry goes as far as the phrase "defensive" as the healthcare sector, which encompasses a wide range of ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
This can be found among the Granolas, a group of 11 European multinationals, selected by US bank Goldman Sachs, which is made ...
After turning over more than 1,300 documents to the Federal Trade Commission, the fast food giant is turning its attention to subpoenas from pharmacy benefit managers the agency accuses of ...
This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...
Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...
Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.
Two counties in the Charlotte area have filed lawsuits in the last few weeks over the price of insulin. Gaston County and ...
Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...